Back to List View Graph View

T-lymphocytes

T-lymphocytes are the antigen-specific effectors of adaptive cellular immunity.

Where the papers sit

11 papers from the last 6 months study t-lymphocytes directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 3 human data · 6 preclinical · 2 unclassified

Themes one subject · 1 paradigm shift

Those 11 are all about one subject.

  • General T-Cell Research

    T-cell research here spans cancer immunology, autoimmune disease, infection, aging, transplantation and therapeutic delivery. Cancer-focused work tests arginine depletion, CD40 agonism, checkpoint blockade, DNA nanostructures and in vivo CAR-T generation. Other studies examine gut microbiota, γδ T-cell responses to CMV, myasthenia gravis and intranasal coronavirus vaccination. No common mechanism, intervention or clinical endpoint establishes a coherent direction across the group.

    11 papers

PARADIGM SHIFT

Tumor-reactive and antiviral T-cell responses are not uniformly conventional αβ responses dominated by exhaustion

The multiple-myeloma and acute-myeloid-leukemia bone-marrow study 42575099Aug and the post-transplant cytomegalovirus study 42472991Jul instead identify functional responses that fall outside that default: marrow tumor-reactive T cells retain a conserved, activatable effector program distinct from the exhausted state described in solid tumors, while CMV reactivation preferentially expands non-Vγ9Vδ2 γδ clones that acquire cytotoxic antiviral phenotypes, with comparatively modest clonal change among conventional CD8⁺ αβ cells. The consequence is a change in therapeutic framing: detecting and engaging latent marrow T-cell immunity and adaptive-like γδ responses becomes as important as reversing exhaustion or expanding conventional αβ effector cells.

Papers

The 11 papers from the last 6 months that study t-lymphocytes directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

General T-Cell Research (11)
  1. Gut microbiota dysbiosis shapes brain T-cell immunity in accelerated aging. Gut microbes · 17 Sept 2026 PMID 42750596
  2. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  3. Integrated experimental and computational evaluation of atractylenolide III from Tubipora musica for anticancer lead identification. Scientific reports · 10 Sept 2026 PMID 42716976
  4. Tumor-driven arginine depletion induces T-cell metabolism reprogramming to suppress atherosclerosis in colorectal cancer. Acta pharmacologica Sinica · 18 Aug 2026 PMID 42608528
  5. An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055
  6. Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment. Cancer cell · 10 Aug 2026 PMID 42575099
  7. Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory. Journal for immunotherapy of cancer · 4 Aug 2026 PMID 42552061
  8. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
  9. γδ T cells show distinct responses to CMV after stem cell transplantation. Journal of molecular medicine (Berlin, Germany) · 19 Jul 2026 PMID 42472991
  10. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  11. Dual-Spatially Confined Assembly of DNA Nanowall Stiffens Tumor Cells to Enhance Adoptive T-Cell Immunotherapy. Journal of the American Chemical Society · 4 Jun 2026 PMID 42241331

By study type

Human data, design not indexed (3)
  1. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  2. Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment. Cancer cell · 10 Aug 2026 PMID 42575099
  3. γδ T cells show distinct responses to CMV after stem cell transplantation. Journal of molecular medicine (Berlin, Germany) · 19 Jul 2026 PMID 42472991
Preclinical: animal, cell and lab studies (6)
  1. Gut microbiota dysbiosis shapes brain T-cell immunity in accelerated aging. Gut microbes · 17 Sept 2026 PMID 42750596
  2. Integrated experimental and computational evaluation of atractylenolide III from Tubipora musica for anticancer lead identification. Scientific reports · 10 Sept 2026 PMID 42716976
  3. Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory. Journal for immunotherapy of cancer · 4 Aug 2026 PMID 42552061
  4. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
  5. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  6. Dual-Spatially Confined Assembly of DNA Nanowall Stiffens Tumor Cells to Enhance Adoptive T-Cell Immunotherapy. Journal of the American Chemical Society · 4 Jun 2026 PMID 42241331
Unclassified: not yet indexed with MeSH (2)
  1. Tumor-driven arginine depletion induces T-cell metabolism reprogramming to suppress atherosclerosis in colorectal cancer. Acta pharmacologica Sinica · 18 Aug 2026 PMID 42608528
  2. An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055